Results 1-20 of 37 for cervical segment:7113182

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Alan Kelly: .... Is it agreed that we will take Mr. Breslin and Mr. Breen's statements as read? Agreed. The director general of the HSE and Mr. McCallion will have to leave in an hour and a half, as the cervical cancer issues with which we are dealing are live ones and they must travel to Limerick. Now that the meeting has commenced, we will allow a round of questioning for the first hour and a...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

...based on a presumption that there is some action that has been taken that has led to that diagnosis, but that is far from established. As has been explained in other forums, the reason we have a cervical screening programme, which is a screening rather than a diagnostic programme, is to limit the number of such cases, but it cannot eliminate them.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Tony O'Brien: Let me revert to where we started our short discussion. The cervical screening programme is designed to detect early cell changes, which can lead to further investigation. There is no-----

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Tony O'Brien: The Deputy is not following the logic. There is no cervical screening programme or any population-based cancer screening programme in the world that can guarantee that there will not subsequently be a cancer. Neither can it guarantee that, in a test that is not fool-proof, there will be no abnormalities missed.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Tony O'Brien: Let me tell the Deputy something that he is unwilling to hear. Ten or 12 years ago when this country embarked on the process of introducing a cervical screening programme, it was known, because it was known everywhere, that that programme would not be infallible.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

...O'Brien: Infallible. The choice was to have a screening programme, one that has since detected 50,000 high-grade abnormalities, leading to early treatment to the probable avoidance of hundreds of cervical cancers and, ultimately, deaths, or not to have it. If one wishes to hold population screening programmes to a test of infallibility, then no country in the world will do them.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

...a test to appear normal and yet for there to subsequently be a finding of cancer leading to a review of that slide which can lead to a changed view. This is well understood in the literature of cervical cytology, which has a rate of accuracy well short of 100%.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

David Cullinane: ...in his organisation. He accused Deputy MacSharry of trying, in the case of Emma Mhic Mhathúna, to create the impression that the false diagnosis had some consequence on her being diagnosed with cervical cancer.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

David Cullinane: ...about her death. It is a very personal tragedy for her. Ms Mhic Mhathúna was told in 2013 that her smear test was normal. Three years later, following a routine smear test, she was diagnosed with cervical cancer. The audit of the 2013 result showed that, in Ms Mhic Mhathúna's case, the first indications of cancer were already there. She was never told. It was the same for...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Bobby Aylward: Is Mr. O'Brien confident that there is no other section within the HSE, besides the cervical screening programme, in which there is a problem that we will hear about next year or in three or six months' time? Is this making the HSE alert to other parts of the service? Are both the system and the roll-out of services fit for purpose? Is Mr. O'Brien happy that this is a once-off and that...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

...McCallion: Sorry, Deputy, all programmes have an assurance process around it and each of those are set out. I am just saying that in terms of the contrast I believe the Deputy made between the cervical programme and the other programmes, there are differences in how they are approached. Clearly, the review is going to look at that to give us assurance that there are no issues in terms...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Tony O'Brien: No. We do not have quite that process anymore. The cervical cancer screening service moved back into the cancer control programme earlier this year. We gave the person a different role. Even were that person to be in the same role, the director would not continue to have this responsibility.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Tony O'Brien: -----without having it in front of me. That number, in the context of 3 million cervical smear tests and 1.12 million women participating in the programme, based on what we know of the reliability and efficacy of population-based screening and as difficult and as harrowing as it is for all of the individuals concerned, is not a number that would raise fundamental concerns...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Tony O'Brien: Yes, and it has always been my view that the central issue here, apart from the obviously tragic situation that individual women face when they go on to experience a diagnosis of cervical cancer, which is a very adverse diagnosis, was the failure to follow through on a plan to communicate results with women. That was the central failure in the programme.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Marc MacSharry: ...on the record a communication that was received by Dr. Keith Swanick, who is also a Member of the Oireachtas, from one of his colleagues. It reads:How can you and your colleagues stand over the cervical controversy. We are inundated with requests for smears with no formal guidance even how to process them, how to claim remuneration. We cannot offer any form of reassurance to any patient...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Bobby Aylward: I understand the cervical screening programme was originally rolled out in 2008. Was the witness part of setting up the original screening programme?

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

...the first chief executive of the National Cancer Screening Service board. That board was created to continue with BreastCheck, to seek to roll out what had been a fledgling, regionally-based Irish cervical cancer screening programme from about 1996, which had not rolled out at that point, and to begin the investigative process around the development of BowelScreen. At the time I was very...

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Ciarán Breen: When we looked at them in terms of the periods of time that they cover, from 2014 up to 2018, there were different years involved. In a cervical smear situation, one would expect to see some claims arise from misdiagnosis. That is something one would expect and certainly looking at the numbers, we did not see a pattern here.

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Mr. Ciarán Breen: Do the Deputies mean our interaction with cervical screening?

Public Accounts Committee: State Claims, Management of Legal Costs and Policy on Open Disclosure
Implications of CervicalCheck Revelations
2016 Financial Statements of the State Claims Agency
2016 Financial Statements of the HSE (10 May 2018)

Catherine Murphy: I wish to ask about the incident that is very current at the moment, namely, that relating to cervical smear tests. Within that €2.2 billion, would the State Claims Agency have captured an amount that would be part of a contingent liability specifically relating to the failure that we are seeing at the moment?